ImmunityBio, Inc. Financials

Market Capitalization $2.33 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-4.61
Forward PE	-4.19
Price to Sales TTM	$74.63
Price to Book MRQ	$-3.93
Enterprise to Revenue	99.03
Enterprise to EBITDA	-10.43

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	100.00%
Operating Margin	-390.08%
Return on Assets TTM	-55.62%
Return on Equity TTM	84.72%

Income Statement

Revenue TTM	$31,222,000
Revenue per Share TTM	$0.04
Quarterly Revenue Growth	41192.50%
Gross Profit TTM	$31,164,000
EBITDA	$-296,588,000
Net Income to Common TTM	$-409,100,992
Diluted EPS TTM	$-0.57
Quarterly Earnings Growth YoY	41192.50%

Balance Sheet

Total Cash MRQ	$61,591,000
Total Cash per Share MRQ	$0.07
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.39
Current Ratio MRQ	2.22
Book Value per Share MRQ	$-0.69

Cash Flow

Operating Cash Flow TTM	$-370,159,008
Levered Free Cash Flow TTM	$-251,767,632

IBRX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	852,904,340
Float Shares	130,919,085
Avg 10 Volume	6,735,030
Avg 30 Volume	None
Shares Short	72,356,035
Short Ratio	6.60
Short % of Shares	31.68%
% Held by Insiders	74.11%
% Held by Institutions	9.24%

Stock Price Summary

Beta	-0.07
Fifty Two Week Low	$1.83
Fifty Two Week High	$7.48
Fifty Two Week Change	-133.82%
Day 50 MA	$2.68
Day 200 MA	$3.32

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date